An Overview of Proprietary Vehicles/Bases for Topical Compounding Medicines and Cosmetics
Abstract
:1. Introduction
2. Vehicles/Bases for Topical Medicines
2.1. Topical Liquids: Solutions, Suspensions, Shampoos, Sprays, Foams, and Lotions
2.2. Topical Semisolids: Creams, Ointments, and Gels
3. Micro- and Nanosystems
4. Compounded Medicines
- The absence of marketed medicines. The pharmaceutical industry often discontinues drug commercialization due to technical or commercial reasons. Also, in the case of rare diseases, there are only a few insufficient options [51];
- Unsuitable pharmaceutical forms for patients with routes of administration unavailable or unconscious patients, or in the case of routes of administration that are difficult to use, such as solid oral forms for children or the elderly;
- Inadequate dosages for the pathophysiological needs of patients such as pediatric, geriatric, and renal or hepatic impairment, or for dosage titration needs;
- Patients intolerant to some substances (e.g., lactose), diabetics (e.g., sucrose), allergic patients (e.g., parabens), or where one needs to avoid drug interactions [52];
- The association of active substances to improve and facilitate the dosage regimen in the case of comorbidities;
- The adequacy of the amount of product to be dispensed, allowing adjustment to the patient’s regimen needs;
- The use of unstable active substances with a short shelf life and complex stability, which may be an obstacle to their marketing;
- Improving therapeutic adherence by optimizing vehicles according to patient preferences (organoleptic characteristics) and disease characteristics;
- Small-scale formulations for clinical trial application [53].
5. Proprietary Vehicles/Bases
6. Search Method
7. Results
8. Discussion
8.1. Topical Liquids: Solutions, Micellar Solutions, Suspensions, Shampoos, Sprays, Foams, and Lotions
8.2. Topical Semisolids: Creams, Ointments, and Gels
8.2.1. Nanosystems
8.2.2. Therapeutic Application
8.2.3. Claims
9. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Council of Europe. European Pharmacopoeia, 11th ed.; Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM): Strasbourg, France, 2022. [Google Scholar]
- Oliveira, R.; Almeida, I.F. Patient-Centric Design of Topical Dermatological Medicines. Pharmaceuticals 2023, 16, 617. [Google Scholar] [CrossRef] [PubMed]
- Maxon, B.; Starch, M. Formulating Skin Care Products with Silicones: Approaches and Strategies. In Handbook of Formulating Dermal Applications; Wiley: Weinheim, Germany, 2016; pp. 59–114. [Google Scholar]
- Aulton, M.E.; Taylor, K. (Eds.) Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 6th ed.; Elsevier: Amsterdam, The Netherlands, 2021; p. 968. [Google Scholar]
- Mayba, J.N.; Gooderham, M.J. A Guide to Topical Vehicle Formulations. J. Cutan. Med. Surg. 2018, 22, 207–212. [Google Scholar] [CrossRef] [PubMed]
- Barnes, T.M.; Mijaljica, D.; Townley, J.P.; Spada, F.; Harrison, I.P. Vehicles for Drug Delivery and Cosmetic Moisturizers: Review and Comparison. Pharmaceutics 2021, 13, 2012. [Google Scholar] [CrossRef] [PubMed]
- Akombaetwa, N.; Ilangala, A.B.; Thom, L.; Memvanga, P.B.; Witika, B.A.; Buya, A.B. Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications. Pharmaceutics 2023, 15, 656. [Google Scholar] [CrossRef]
- Lein, A.; Ng, S.W. Dermal. In Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products, 2nd ed.; Le Brun, P., Crauste-Manciet, S., Krämer, I., Smith, J., Woerdenbag, H., Eds.; Springer International Publishing: Cham, Switzerland, 2023; pp. 439–471. [Google Scholar]
- Swarbrick, J. Encyclopedia of Pharmaceutical Technology, 3th ed.; Swarbrick, J., Ed.; CRC Press: Boca Raton, FL, USA, 2006. [Google Scholar]
- Allen, L.V. The Art, Science, and Technology of Pharmaceutical Compounding, 5th ed.; American Pharmacists Association: Washington, DC, USA, 2016. [Google Scholar]
- Umar, A.K.; Butarbutar, M.; Sriwidodo, S.; Wathoni, N. Film-Forming Sprays for Topical Drug Delivery. Drug Des. Devel Ther. 2020, 14, 2909–2925. [Google Scholar] [CrossRef]
- Schramm, L.L. Personal Care Product Applications. In Emulsions, Foams, and Suspensions; Schramm, L.L., Ed.; Wiley: Weinheim, Germany, 2005; pp. 337–346. [Google Scholar]
- Schramm, L.L. Dispersion and Dispersed Species Characterization. In Emulsions, Foams, and Suspensions; Schramm, L.L., Ed.; Wiley: Weinheim, Germany, 2005; pp. 13–51. [Google Scholar]
- Elewski, B.E.; Abramovits, W.; Kempers, S.; Schlessinger, J.; Rosen, T.; Gupta, A.K.; Abraham, S.; Rowell, R. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J. Drugs Dermatol. 2007, 6, 1001–1008. [Google Scholar]
- Leonardi, C.; Bagel, J.; Yamauchi, P.; Pariser, D.; Xu, Z.; Olesen, M.; Østerdal, M.L.; Stein Gold, L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients with Psoriasis Vulgaris—A Randomized Phase III Study (PSO-FAST). J. Drugs Dermatol. 2015, 14, 1468–1477. [Google Scholar]
- Fowler, J.; Fowler, L. Physician and Patient Assessment of Triamcinolone Acetonide Spray for Steroid-responsive Dermatoses. J. Clin. Aesthet. Dermatol. 2010, 3, 27–31. [Google Scholar]
- Schlager, J.G.; Rosumeck, S.; Werner, R.N.; Jacobs, A.; Schmitt, J.; Schlager, C.; Nast, A. Topical treatments for scalp psoriasis. Cochrane Database Syst. Rev. 2016, 2, Cd009687. [Google Scholar] [CrossRef]
- Teixeira, A.; Teixeira, M.; Almeida, V.; Gaio, R.; Torres, T.; Magina, S.; Cunha, C.; Sousa Lobo, J.M.; Almeida, I.F. Does the Vehicle Matter? Real-World Evidence on Adherence to Topical Treatment in Psoriasis. Pharmaceutics 2021, 13, 1539. [Google Scholar] [CrossRef]
- Kvenshagen, B.K.; Carlsen, K.H.; Mowinckel, P.; Berents, T.L.; Carlsen, K.C. Can early skin care normalise dry skin and possibly prevent atopic eczema? A pilot study in young infants. Allergol. Immunopathol. 2014, 42, 539–543. [Google Scholar] [CrossRef] [PubMed]
- Emtestam, L.; Svensson, Å.; Rensfeldt, K. Treatment of seborrhoeic dermatitis of the scalp with a topical solution of urea, lactic acid, and propylene glycol (K301): Results of two double-blind, randomised, placebo-controlled studies. Mycoses 2012, 55, 393–403. [Google Scholar] [CrossRef] [PubMed]
- Ortonne, J.P.; Nikkels, A.F.; Reich, K.; Ponce Olivera, R.M.; Lee, J.H.; Kerrouche, N.; Sidou, F.; Faergemann, J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0.05% combined with ketoconazole shampoo 2%: A randomized, controlled study. Br. J. Dermatol. 2011, 165, 171–176. [Google Scholar] [CrossRef] [PubMed]
- Schramm, L.L. Interfacial Energetics. In Emulsions, Foams, and Suspensions; Schramm, L.L., Ed.; Wiley: Weinheim, Germany, 2005; pp. 53–100. [Google Scholar]
- Lukic, M.; Pantelic, I.; Savic, S. An Overview of Novel Surfactants for Formulation of Cosmetics with Certain Emphasis on Acidic Active Substances. Tenside Surfactants Deterg. 2016, 53, 7–19. [Google Scholar] [CrossRef]
- Ajazuddin; Alexander, A.; Khichariya, A.; Gupta, S.; Patel, R.J.; Giri, T.K.; Tripathi, D.K. Recent expansions in an emergent novel drug delivery technology: Emulgel. J. Control. Release 2013, 171, 122–132. [Google Scholar] [CrossRef] [PubMed]
- Danby, S.G.; Draelos, Z.D.; Gold, L.F.S.; Cha, A.; Vlahos, B.; Aikman, L.; Sanders, P.; Wu-Linhares, D.; Cork, M.J. Vehicles for atopic dermatitis therapies: More than just a placebo. J. Dermatol. Treat. 2022, 33, 685–698. [Google Scholar] [CrossRef] [PubMed]
- Öztürk, A.A.; Yenilmez, E. Pharmacological and Pharmaceutical Technological Overview for Seborrheic Dermatitis: A Review About Topical Application and New Approaches. Acta Pharm. Sci. 2018, 56, 57–80. [Google Scholar] [CrossRef]
- Hoffman, L.K.; Bhatia, N.; Zeichner, J.; Kircik, L.H. Topical Vehicle Formulations in the Treatment of Acne. J. Drugs Dermatol. 2018, 17, S6–S10. [Google Scholar]
- Jackson, J.M.; Pelle, M. Topical rosacea therapy: The importance of vehicles for efficacy, tolerability and compliance. J. Drugs Dermatol. 2011, 10, 627–633. [Google Scholar]
- Mason, A.R.; Mason, J.; Cork, M.; Dooley, G.; Hancock, H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst. Rev. 2013, 3, Cd005028. [Google Scholar] [CrossRef]
- Rajkapoor, B.; Sughir, A.; Damodar, G. Oleogel: A promising base for transdermal formulations. Asian J. Pharm. 2012, 6, 1–9. [Google Scholar] [CrossRef]
- Almeida, I.F.; Gaio, A.R.; Bahia, M.F. Hedonic and Descriptive Skinfeel Analysis of Two Oleogels: Comparison with Other Topical Formulations. J. Sens. Stud. 2008, 23, 92–113. [Google Scholar] [CrossRef]
- Kuzina, M.A.; Kartsev, D.D.; Stratonovich, A.V.; Levkin, P.A. Organogels versus Hydrogels: Advantages, Challenges, and Applications. Adv. Funct. Mater. 2023, 33, 2301421. [Google Scholar] [CrossRef]
- Jun Yang, S.; Yoon, K.S. Preparation and Evaluation of Pluronic Lecithin Organogels in Cosmetics. J. Cosmet. Sci. 2021, 72, 325–346. [Google Scholar]
- Barbosa, A.I.; Torres, T.; Lima, S.A.C.; Reis, S. Hydrogels: A Promising Vehicle for the Topical Management of Atopic Dermatitis. Adv. Ther. 2021, 4, 2100028. [Google Scholar] [CrossRef]
- Schlesinger, T.; Rowland Powell, C. Efficacy and safety of a low molecular weight hyaluronic Acid topical gel in the treatment of facial seborrheic dermatitis final report. J. Clin. Aesthet. Dermatol. 2014, 7, 15–18. [Google Scholar]
- Van Zuuren, E.J.; Fedorowicz, Z.; Christensen, R.; Lavrijsen, A.; Arents, B.W.M. Emollients and moisturisers for eczema. Cochrane Database Syst. Rev. 2017, 2, Cd012119. [Google Scholar] [CrossRef]
- Antunes, A.F.; Pereira, P.; Reis, C.; Rijo, P.; Reis, C. Nanosystems for Skin Delivery: From Drugs to Cosmetics. Curr. Drug Metab. 2017, 18, 412–425. [Google Scholar] [CrossRef]
- Perumal, S.; Atchudan, R.; Lee, W. A Review of Polymeric Micelles and Their Applications. Polymers 2022, 14, 2510. [Google Scholar] [CrossRef] [PubMed]
- Aziz, Z.A.A.; Mohd-Nasir, H.; Ahmad, A.; Mohd, S.H.; Peng, W.L.; Chuo, S.C.; Khatoon, A.; Umar, K.; Yaqoob, A.A.; Mohamad Ibrahim, M.N. Role of Nanotechnology for Design and Development of Cosmeceutical: Application in Makeup and Skin Care. Front. Chem. 2019, 7, 739. [Google Scholar] [CrossRef]
- Makhmalzade, B.S.; Chavoshy, F. Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders. J. Adv. Pharm. Technol. Res. 2018, 9, 2–8. [Google Scholar] [CrossRef] [PubMed]
- Parra, A.; Jarak, I.; Santos, A.; Veiga, F.; Figueiras, A. Polymeric Micelles: A Promising Pathway for Dermal Drug Delivery. Materials 2021, 14, 7278. [Google Scholar] [CrossRef] [PubMed]
- Grumezescu, A.M. Chapter 6—Liposomes as topical drug delivery systems: State of the arts. In Biomedical Applications of Nanoparticles; Grumezescu, A.M. William Andrew Publishing: Amsterdam, The Netherlands, 2019; pp. 149–161. [Google Scholar]
- Barani, M.; Sangiovanni, E.; Angarano, M.; Rajizadeh, M.A.; Mehrabani, M.; Piazza, S.; Gangadharappa, H.V.; Pardakhty, A.; Mehrbani, M.; Dell’Agli, M.; et al. Phytosomes as Innovative Delivery Systems for Phytochemicals: A Comprehensive Review of Literature. Int. J. Nanomed. 2021, 16, 6983–7022. [Google Scholar] [CrossRef] [PubMed]
- Purohit, S.J.; Tharmavaram, M.; Rawtani, D.; Prajapati, P.; Pandya, H.; Dey, A. Niosomes as cutting edge nanocarrier for controlled and targeted delivery of essential oils and biomolecules. J. Drug Deliv. Sci. Technol. 2022, 73, 103438. [Google Scholar] [CrossRef]
- Nastiti, C.; Ponto, T.; Abd, E.; Grice, J.E.; Benson, H.A.E.; Roberts, M.S. Topical Nano and Microemulsions for Skin Delivery. Pharmaceutics 2017, 9, 37. [Google Scholar] [CrossRef] [PubMed]
- Tiwari, N.; Osorio-Blanco, E.R.; Sonzogni, A.; Esporrín-Ubieto, D.; Wang, H.; Calderón, M. Nanocarriers for Skin Applications: Where Do We Stand? Angew. Chem. Int. Ed. 2022, 61, e202107960. [Google Scholar] [CrossRef]
- Hofmann-Amtenbrink, M.; Hofmann, H.; Hool, A.; Roubert, F. Nanotechnology in medicine: European research and its implications. Swiss Med. Wkly. 2014, 144, w14044. [Google Scholar] [CrossRef]
- Shrewsbury, R.P. Applied Pharmaceutics in Contemporary Compounding; Morton Publishing Company: Englewood, CO, USA, 2015. [Google Scholar]
- Elder, D.L. A Practical Guide to Contemporary Pharmacy Practice and Compounding; Wolters Kluwer: Philadelphia, PA, USA, 2017. [Google Scholar]
- Carvalho, M.; Almeida, I.F. The Role of Pharmaceutical Compounding in Promoting Medication Adherence. Pharmaceuticals 2022, 15, 1091. [Google Scholar] [CrossRef]
- Dooms, M.; Carvalho, M. Compounded medication for patients with rare diseases. Orphanet J. Rare Dis. 2018, 13, 1. [Google Scholar] [CrossRef]
- Nagel-Edwards, K.M.; Ko, J.Y. Excipient choices for special populations. Int. J. Pharm. Compd. 2008, 12, 426–430. [Google Scholar]
- Allen, L.V., Jr. Compounding for Investigational and Clinical Studies. Int. J. Pharm. Compd. 2022, 26, 201–209. [Google Scholar] [PubMed]
- Watson, C.J.; Whitledge, J.D.; Siani, A.M.; Burns, M.M. Pharmaceutical Compounding: A History, Regulatory Overview, and Systematic Review of Compounding Errors. J. Med. Toxicol. 2021, 17, 197–217. [Google Scholar] [CrossRef] [PubMed]
- Curtis, C.; Sacks, G.S. Compounding parenteral nutrition: Reducing the risks. Nutr. Clin. Pract. 2009, 24, 441–446. [Google Scholar] [CrossRef] [PubMed]
- Sánchez-Regaña, M.; Llambí-Mateos, F.; Salleras-Redonnet, M.; Iglesias Sancho, M.; Collgros Totosaus, H.; Umbert-Millet, P. Compounding as a Current Therapeutic Option in Dermatology. Actas Dermo-Sifiliográficas 2013, 104, 738–756. [Google Scholar] [CrossRef] [PubMed]
- Abarca Lachén, E.; Hernando Martínez, P.; Gilaberte Calzada, Y. The Most Useful Pharmaceutical Formulations (Individualized Medications) in Pediatric Dermatology: A Review. Actas Dermo-Sifiliográficas 2021, 112, 302–313. [Google Scholar] [CrossRef] [PubMed]
- Acofarma. Acofarma Formulas Magistrales. Available online: https://formulasmagistrales.acofarma.com (accessed on 20 October 2023).
- Fragron. Fagron Advanced Derma. Available online: https://d2p6xt2uil81ec.cloudfront.net/fagron/uploads/2021/11/25100332/FAD-productflyer.pdf (accessed on 20 October 2023).
- Guinama. Bases. Available online: https://www.guinama.com/bases-jarabes-y-emulsionantes/bases.html (accessed on 20 October 2023).
- Medisca. Cream Base Reference Chart. Available online: https://www.medisca.com/Files/ReferenceCharts/Cream%20&%20Gel%20Bases%20Reference%20Chart%20-%20MUS.pdf (accessed on 20 October 2023).
- PCCA. PCCA’s Dermatology Bases. Available online: https://www.pccarx.com/BuyProducts/CompoundingBaseTechnology/DermatologyBases (accessed on 20 October 2023).
- RX, S. Technical Data Sheets. Available online: https://specializedrx.com/pages/tech-sheets (accessed on 20 October 2023).
- Medical, L. Creams & Bases. Available online: https://www.letcomedical.com/creams-bases (accessed on 20 October 2023).
- Issuu. Letco Catalog 2021. Available online: https://issuu.com/letcomed/docs/let_2021_catalog (accessed on 20 October 2023).
- Compounding Chemicals.com.au. Spectrum Chemical MFG Corp. Available online: https://compoundingchemicals.com.au/pages/bases (accessed on 20 October 2023).
- Iversen, L.; Jakobsen, H.B. Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. Dermatol. Ther. 2016, 6, 273–285. [Google Scholar] [CrossRef] [PubMed]
- Hoc, D.; Haznar-Garbacz, D. Foams as unique drug delivery systems. Eur. J. Pharm. Biopharm. 2021, 167, 73–82. [Google Scholar] [CrossRef] [PubMed]
- Charbonnier, V.; Morrison, B.M.; Paye, M.; Maibach, H.I. Subclinical, non-erythematous irritation with an open assay model (washing): Sodium lauryl sulfate (SLS) versus sodium laureth sulfate (SLES). Food Chem. Toxicol. 2001, 39, 279–286. [Google Scholar] [CrossRef]
- Liao, Y.; Sun, Y.; Wang, Z.; Zhong, M.; Li, R.; Yan, S.; Qi, B.; Li, Y. Structure, rheology, and functionality of emulsion-filled gels: Effect of various oil body concentrations and interfacial compositions. Food Chem. X 2022, 16, 100509. [Google Scholar] [CrossRef]
- Baki, G.; Alexander, K.S. Introduction to Cosmetic Formulation and Technology; John Wiley & Sons: Hoboken, NJ, USA, 2015. [Google Scholar]
- Epstein, H. Pre-formulation Design and Considerations. In Handbook of Formulating Dermal Applications; Wiley: Weinheim, Germany, 2016; pp. 1–27. [Google Scholar]
- Choi, M.J.; Maibach, H.I. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol. Physiol. 2005, 18, 209–219. [Google Scholar] [CrossRef]
- Okoro, U.; John, D.N.O.; Anthony, A.A. Nanoparticles for Dermal and Transdermal Drug Delivery. In Application of Nanotechnology in Drug Delivery; Ali Demir, S., Ed.; IntechOpen: Rijeka, Croatia, 2014; p. 6. [Google Scholar]
- Torres, A.; Rego, L.; Martins, M.S.; Ferreira, M.S.; Cruz, M.T.; Sousa, E.; Almeida, I.F. How to Promote Skin Repair? In-Depth Look at Pharmaceutical and Cosmetic Strategies. Pharmaceuticals 2023, 16, 573. [Google Scholar] [CrossRef] [PubMed]
Property | Frequency (%) |
---|---|
Physical form | Semisolid 84.1 |
Liquid 15.9 | |
Type of dosage form | Cream 52.2 |
Ointments 12.3 | |
Gel 19.6 | |
Lotions 4.3 | |
Solutions 2.2 | |
Suspensions 0.7 | |
Lacquer 0.7 | |
Shampoo 2.9 | |
Foam 5.1 | |
With nanosystems | 5.8 |
Body area | Unspecified 68.8 |
Face 0.7 | |
Body 3.6 | |
Face and body 0.7 | |
Scalp 4.4 | |
Face, body, and hair 2.2 | |
Oral mucosa 2.2 | |
Genital 15.9 | |
Retal 0.7 | |
Nails 0.7 | |
Suggested therapeutic application | Dermatology 84.1 |
Cosmetics 15.9 | |
Pain management 17.4 | |
Immunotherapy 2.9 | |
HTR 19.6 | |
Not specified 2.9 | |
Absence of *: | Sulphates 13.0 |
Petrolatum 26.8 | |
Parabens 40.6 | |
Fragrances 15.2 | |
Preservatives 4.4 | |
Colorings 13.8 | |
Skin type | Sensitive skin 12.3 |
Oily skin 13.0 | |
Injured skin 18.1 | |
Dry skin 18.1 | |
Hypoallergenic | 13.0 |
Non-irritating | 8.7 |
Anhydrous | 12.3 |
Occlusive | 6.5 |
Non-greasy | 20.3 |
Moisturizing properties | 27.5 |
Compatibilities/incompatibilities | Mentioned 58.0 |
Not mentioned 42.0 | |
pH-stable ** | 21.7 |
Good sensory properties *** | 24.6 |
With natural excipients | 21.7 |
Composition: | Complete 50.0 |
Incomplete 15.2 | |
Not available 34.8 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Torres, A.; Almeida, I.F.; Oliveira, R. An Overview of Proprietary Vehicles/Bases for Topical Compounding Medicines and Cosmetics. Cosmetics 2024, 11, 16. https://doi.org/10.3390/cosmetics11010016
Torres A, Almeida IF, Oliveira R. An Overview of Proprietary Vehicles/Bases for Topical Compounding Medicines and Cosmetics. Cosmetics. 2024; 11(1):16. https://doi.org/10.3390/cosmetics11010016
Chicago/Turabian StyleTorres, Ana, Isabel F. Almeida, and Rita Oliveira. 2024. "An Overview of Proprietary Vehicles/Bases for Topical Compounding Medicines and Cosmetics" Cosmetics 11, no. 1: 16. https://doi.org/10.3390/cosmetics11010016
APA StyleTorres, A., Almeida, I. F., & Oliveira, R. (2024). An Overview of Proprietary Vehicles/Bases for Topical Compounding Medicines and Cosmetics. Cosmetics, 11(1), 16. https://doi.org/10.3390/cosmetics11010016